| Literature DB >> 34833485 |
Hyun Goo Kang1, Hyun Ki Lee2, Kyu Bong Cho3, Sang Il Park1.
Abstract
BACKGROUND AND OBJECTIVES: acute kidney injury (AKI), formerly called acute renal failure (ARF), is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products-measured by blood urea nitrogen (BUN) and serum creatinine levels-over the course of hours to weeks. AKI occurs in about 20% of all hospitalized patients and is more common in the elderly. Therefore, it is necessary to prevent the occurrence of AKI, and to detect and treat early, since it is known that a prolonged period of kidney injury increases cardiovascular complications and the risk of death. Despite advances in modern medicine, there are no consistent treatment strategies for preventing the progression to chronic kidney disease. Through many studies, the safety and efficacy of natural products have been proven, and based on this, the time and cost required for new drug development can be reduced. In addition, research results on natural products are highly anticipated in the prevention and treatment of various diseases. In relation to AKI, many papers have reported that many natural products can prevent and treat AKI.Entities:
Keywords: acute kidney injury; antioxidant; natural products; prevention
Mesh:
Substances:
Year: 2021 PMID: 34833485 PMCID: PMC8623373 DOI: 10.3390/medicina57111266
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
List of some natural products with potential prevention of AKI action.
| Name | Model | Prevention/ | Minimal | Described Effects and | References |
|---|---|---|---|---|---|
| Flavonoids | |||||
| Quercetin | NRK-52E cells and HK-2 cells | Treatment | 10 µM | Reducing the levels of malondialdehyde, lipid ROS and increasing the levels of glutathione | [ |
| Luteolin | Cisplatin-induced AKI in mice | Treatment | 50 mg/kg | Increased the levels of p53 and its phosphorylation, decreased the levels of PUMA-α, Bax and caspase-3 activity | [ |
| Apigenin | Renal ischemia/reperfusion in rats | Prevention | 20 mg/kg | Increased the expressions of Bcl-2, p-Akt, PI3K, and down-regulated the expressions of Caspase3 and Bax | [ |
| Kaempferol | Cisplatin-induced AKI in mice | Prevention | 100 mg/kg | Suppressed levels of TNF-α, iNOS, IL-12, activation of NF-κB, phosphorylation of IκBα and nuclear translocation of p65 | [ |
| Icariin | Pregnancy-induced hypertension mice | Treatment | 100 mg/kg | Improved urinary protein excretion levels and renal tissue damage, upregulation of nephrin expression and downregulation of ANG II | [ |
| Myricetin | Cisplatin-induced AKI in mice | Prevention | 30 mg/kg | Reduced blood BUN, serum Cr, caspase-3, TNF-α, IL-6, COXI and COXII, MDA levels and, increased GSH level and catalase activity | [ |
| Fisetin | LPS-induced septic AKI mice | Treatment | 100 mg/kg | Inhibited expression of IL-6, IL-1β, TNF-α, HMGB1, iNOS and COX-2, suppressed of Bcl-2, BAX and cleaved caspase-3 | [ |
| Galangin | Cisplatin-induced AKI in mice | Prevention | 125 mg/kg | Increased SOD, GPx, CAT and GSH levels, inactivated Nrf2, HO-1 and GCLC, inhibitions of ERK and NF-κB signaling pathways | [ |
| Tangeretin | Cisplatin-induced AKI in rats | Prevention | 8 mg/kg | Reduced MDA, increased GSH, CAT, and SOD activities, elevated Nrf2 expression, downstream effectors IL-1β and TNF-α expression | [ |
| Genistein | Renal ischemia/reperfusion in rats | Prevention | 15 mg/kg | Increased gene expression levels of TLR4 and TNF-α | [ |
| Polyphenols | |||||
| Ellagic acid | Cisplatin-induced AKI in mice | Treatment | 75 mg/kg | Decreased serum creatinine and reduction of active caspase-3 expression | [ |
| Chlorogenic acid | LPS-induced AKI mice | Treatment | 30 mg/kg | Inhibiting TLR4/NF-κB signaling pathway, and reduction of active caspase-3 | [ |
| Gallic acid | Renal ischemia/reperfusion in rats | Prevention | 100 mg/kg | Improve the levels of renal MDA, serum GSH, and GPX activity | [ |
| Vanillic acid | Cisplatin-induced AKI in rats | Prevention | 50 mg/kg | Elevated levels of renal function markers and reduced antioxidant status | [ |
| Resveratrol | Cisplatin-induced AKI in rats | Treatment | 30 mg/kg | Inhibiting IRE1-NF-κB pathway | [ |
| Anthocyanin | Renal ischemia/reperfusion in rats | Prevention | 50 mg/Kg | Reduced the elevated levels of IL-1β, IL-6, TNF-α, and MCP-1 | [ |
| Curcumin | Glycerol-induced AKI in Rats | Prevention/Treatment | 200 mg/kg | Inhibiting regulation of the AMPK and Nrf2/HO-1 signaling pathway and ameliorated activating the PI3K/Akt pathway | [ |
| Salvianolic Acid B | Cisplatin-induced AKI in rats | Prevention | 50 mg/Kg | Activation of the PI3K/Akt/Nrf2 pathway | [ |
| Bakuchiol | Sepsis-induced AKI mice | Prevention | 45 mg/kg | Blockade of the NF-κB and p38 MAPK signaling pathway | [ |
| Polydatin | Sepsis-induced AKI mice | Prevention | 30 mg/kg | Blocked by inhibiting SIRT1, and suppressed NLRP3 | [ |
| Eugenol | Acute pancreatitis rats | Prevention | 15 mg/kg | Mild TNF-α activity and low Serum urea and creatinine levels | [ |
| p-Coumaric acid | Renal ischemia/reperfusion in rats | Prevention | 100 mg/kg | Improved the Cr and BUN levels, reduction in tissue MDA, TNF-α, IL-1β | [ |
| Caffeic acid | Cisplatin-induced AKI in rats | Prevention | 100 mg/kg | Increase in plasma activities of ALT, AST, ALP, and plasma levels of urea, reduced SOD, CAT, GST and GPx | [ |
| Terpenoids | |||||
| Glycyrrhetinic acid | Methotrexate-induced nephrotoxicity in rats | Prevention | 100 mg/kg | Increase in circulating kidney function markers and TNF-α, up-regulating the Nrf2/ARE signaling | [ |
| Ursolic acid | Sepsis-induced AKI mice | Treatment | 20 mg/kg | Inhibiting reactive oxygen species, TNF-α, IL-1β, IL-6, and Nf-κB | [ |
| Oleanolic acid | Cisplatin-induced AKI in mice | Treatment | 40 mg/kg | Inhibiting in caspase-3 and -9 activations and PARP cleavage | [ |
| Genipin | LPS-induced AKI in mice | Prevention | 15 mg/kg | Increasing the UCP2 content Ameliorating mitochondrial dysfunction, anti-inflammation, and antioxidative activities | [ |
| Pinitol | Cisplatin-induced AKI in mice | Treatment | 10 mg/kg | Reduction in oxidative stress and cytokines including TNF-α, IL-1β and IL-6. | [ |
| Linalool | Cisplatin-induced AKI in rats | Prevention | 50 mg/kg | Managed oxidation systems of Nrf2-mediated pathway and diminished TNF-α, IL-1β, IL-6, and NF-κB | [ |
| Geraniol | Cisplatin-induced AKI in rats | Treatment | 100 mg/kg | Abrogated oxidative stress and downregulated the MAPK, STAT-1, p53, p21 and MMP9 | [ |
Abbreviation: AKI; Acute kidney injury, LPS; Lipopolysaccharides.
Figure 1Oxidative stress and inflammatory response mechanisms involved in the pathogenesis of aucte kidney injury and some effect compounds. Abbreviation ROS; Reactive oxygen species, CAT; catalase, GPX; Glutathione peroxidase.
Figure 2Chemical structures of flavonoids with potential preventive effects of aucte kidney injury. (A) Quercetin; (B) Luteolin; (C) Apigenin; (D) Kaempferol; (E) Icariin; (F) Myricetin; (G) Fisetin; (H) Galangin; (I) Tangeretin; (J) Genistein.
Figure 3Chemical structures of polyphenols with potential preventive effects for aucte kidney injury. (A) Ellagic acid; (B) Chlorogenic acid; (C) Gallic acid; (D) Vanillic acid; (E) Resveratrol; (F) Anthocyanin; (G) Curcumin; (H) Salvianolic Acid B; (I) Bakuchiol; (J) Polydatin; (K) Eugenol; (L) p-Coumaric acid; (M) Caffeic acid.
Figure 4Chemical structures of terpenoids with potential preventive effects of aucte kidney injury. (A) Glycyrrhetinic acid; (B) Ursolic acid; (C) Oleanolic acid; (D) Genipin; (E) Pinitol; (F) Linalool; (G) Geraniol.